At the recent BHBIA meeting on the new General Data Protection Regulation I was initially happy to sit back and watch but this roller coaster of a ride not only gripped me but held me to the end. For someone who knew nothing about Data Protection and had assumed it was irrelevant to his daily life this was a timely and somewhat jolting wake-up call. For the gung-ho Brexiteers the tacit acceptance that we in the UK would have to accept this EU legislation if we wanted to do business with EU clients was perhaps an early warning of things to come. To be clear, anyone dealing with personal data, especially sensitive data (eg health, genetics, biometrics etc) should make enquiries pdq (pretty damn quick!) about what impact this legislation will have. There seems little doubt that large organisations should have this covered but smaller organisations may struggle with the greater financial burden of the additional regulatory oversight as well as the potential impact on professional indemnity insurance premiums. With EU legislation set for introduction May 2018 the clock is ticking and all manner of organizations dealing with personal data must review all of their procedures with respect to data gathering, data storage, transfer, analytics and subsequent safe destruction. Take a look at the BHBIA website https://www.bhbia.org.uk/home.aspx where members can download the presentations from six different stakeholders in the healthcare field.
The author was a Pharmaceutical Analyst at Lehman Brothers for 23 years as well as being involved with the PharmaFutures projects www.pharmafutures.org but is now writing independently. Stewart Adkins also “carried the bag” for Dista Products (Lilly Industries )in the early 1980s. Currently, Stewart Adkins is a Director of Pharmaforensic Limited www.pharmaforensic.co.uk and runs his own consultancy Stewart Adkins Advisors Limited.
Stewart Adkins was a Pharmaceutical Analyst at Lehman Brothers for 23 years and was involved with the Pharmafutures projects.